Forskning
Udskriv Udskriv
Switch language
Region Hovedstaden - en del af Københavns Universitetshospital
Udgivet

Synchronous and metachronous liver metastases in patients with colorectal cancer

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  1. Improving colonoscopy quality through individualised training programmes

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Characteristics of patients with COVID-19 pneumonia at Hvidovre Hospital, March-April 2020

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Trends of ankyloglossia and lingual frenotomy in hospital settings among children in Denmark

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  4. Distribution of risk alleles in patients with age-related macular degeneration

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  5. Outcomes and follow-up programmes in extreme preterm children in Denmark in the EPICE/SHIPS cohort

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

Vis graf over relationer

INTRODUCTION: Liver metastases are the most common complication to colorectal cancer, and the presence of metastatic disease severely impacts the overall prognosis of the disease. Since the diagnostic work-up of metastasised colorectal cancer has undergone tremendous changes in past decades, an impact on the incidence of metastatic disease is anticipated. The aim of this study was to evaluate the incidence and prognosis of liver metastasis in patients with colorectal cancer.

METHODS: From 1 January 2005 to 31 December 2011, all patients with a primary diagnosis of colorectal cancer were identified. Data on metastatic dissemination to the liver were collected from medical charts. Patients were followed until death or the end of the study period (31 December 2016).

RESULTS: Among the total study population of 1,672 patients, 23.6% of patients were diagnosed with liver metastases. The incidence of synchronous and metachronous metastases was 16% and 7.7%, respectively. Patients with synchronous and metachronous metastases had a median survival of ten (95% confidence interval (CI): 7.5-12.5) and 43 (95% CI: 35.8-50.2) months, respectively, compared with a median survival of 86 (95% CI: 73.5-98.5) months for patients without liver metastases.

CONCLUSIONS: The incidence of synchronous metastases has remained high despite improved diagnostic technology. Patient survival remains significantly lower when metastatic disease is present, even though treatment options for liver metastases have improved.

FUNDING: none.

TRIAL REGISTRATION: not relevant.

OriginalsprogEngelsk
TidsskriftDanish Medical Journal
Vol/bind65
Udgave nummer12
Sider (fra-til)A5524
ISSN1603-9629
StatusUdgivet - dec. 2018

ID: 56479968